Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 9/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600206 | 0.91 | RYR2 (0.59) | RYR2KCNH2MCHR1MEN1KMT2A | |
| SCHEMBL2137575 | 0.90 | RYR2 (0.76) | RYR2KCNH2MCHR1 | |
| SCHEMBL2600199 | 0.89 | RYR2 (0.60) | RYR2KCNH2MCHR1 | |
| SCHEMBL2600718 | 0.88 | RYR2 (0.61) | RYR2KCNH2MCHR1ALDH1A1KDM4E | |
| SCHEMBL2600205 | 0.88 | RYR2 (0.55) | RYR2KCNH2MCHR1MEN1KMT2A | |
| SCHEMBL2600208 | 0.86 | RYR2 (0.53) | RYR2KCNH2MCHR1MEN1KMT2A | |
| SCHEMBL13632685 | 0.85 | KCNH2 (0.78) | RYR2KCNH2KDM4E | |
| SCHEMBL2600715 | 0.85 | RYR2 (0.66) | RYR2KCNH2MCHR1 | |
| SCHEMBL6867808 | 0.81 | RYR2 (0.86) | RYR2KCNH2 | |
| SCHEMBL12240358 | 0.80 | RYR2 (0.59) | RYR2KCNH2ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933129-B2 | Compounds and methods for modulating activity of calcium release channels | STATE OF OREGON BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2015-01-13 | — | — | US | disclosed |
| US-20120101085-A1 | Compounds And Methods For Modulating Activity Of Calcium Release Channels | State of Oregon by and through the State Board of Higher Education on behalf of Portland State Univ. (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101085-A1 | Compounds And Methods For Modulating Activity Of Calcium Release Channels | RYR2, RYR1, CACNA1E | RYR2 1/4885KCNH2 87/4885MCHR1 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.